# Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency

> **NCT05907746** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 7 (actual)

## Conditions studied

- GATA2
- Immunodeficiency

## Interventions

- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Tacrolimus
- **DRUG:** Post-Transplant Cyclophosphamide
- **RADIATION:** Total Body Irradiation
- **PROCEDURE:** Hematopoietic Cell Transplant
- **DRUG:** Briquilimab
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT05907746
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-29
- **Primary completion:** 2025-10-16
- **Final completion:** 2028-07-31
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05907746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05907746, "Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05907746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*